A Study to Assess Pharmacokinetics, Safety and Tolerability of Multiple Doses of CAT-354 in Subjects With Moderate Asthma

NCT ID: NCT00974675

Last Updated: 2017-05-02

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1
• Total Enrollment: 23 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-09-29
• Study Completion Date: 2007-08-03

Brief Summary

The study includes participants with moderate asthma who were randomly assigned to receive the study medication (CAT-354) or placebo.

Detailed Description

This study is a randomized, double-blind, placebo controlled study. Following confirmation of eligibility, subjects with moderate asthma will be recruited sequentially to one of three dose groups and randomly assigned within dose group to either CAT-354 or placebo. Doses of the assigned treatment will be administered on three occasions 28 days apart. Follow up for pharmacokinetic blood sampling and safety will continue to Day 147 post-first dose (91 days post-third dose).

Conditions

Moderate Asthma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

CAT-354 1 mg/kg

CAT-354 1 milligram/kilogram (mg/kg) of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.

Group Type: EXPERIMENTAL

CAT-354 1mg/kg

Intervention Type: BIOLOGICAL

CAT-354 1 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.

CAT-354 5 mg/kg

CAT-354 5 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.

Group Type: EXPERIMENTAL

CAT-354 5 mg/kg

Intervention Type: BIOLOGICAL

CAT-354 5 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.

CAT-354 10mg/kg

CAT-354 10 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.

Group Type: EXPERIMENTAL

CAT-354 10mg/kg

Intervention Type: BIOLOGICAL

CAT-354 10 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.

Placebo

Placebo matched to CAT-354 intravenous infusion over 30 minutes on Day 0, 28 and 56.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

Placebo matched to CAT-354 intravenous infusion over 30 minutes on Day 0, 28 and 56.

Interventions

CAT-354 1mg/kg

CAT-354 1 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.

Intervention Type: BIOLOGICAL

CAT-354 5 mg/kg

CAT-354 5 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.

Intervention Type: BIOLOGICAL

CAT-354 10mg/kg

CAT-354 10 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.

Intervention Type: BIOLOGICAL

Placebo

Placebo matched to CAT-354 intravenous infusion over 30 minutes on Day 0, 28 and 56.

Intervention Type: OTHER

Other Intervention Names

Tralokinumab; Tralokinumab; Tralokinumab

Eligibility Criteria

Inclusion Criteria

• Males or infertile females
• Subjects with asthma, well controlled on inhaled corticosteroid and taken as required (PRN) short acting beta 2 agonist therapy only
• Unchanged dose of inhaled corticosteroid for 3 months prior to Day 0 and no expected need for change in dose during study
• Forced expiratory volume in 1 second (FEV1) greater than or equal to 80% predicted at Screening (Baseline)
• 18-60 years
• General Practitioner diagnosis of asthma of 1 year's minimum duration (with respect to Day 0)
• No significant abnormality on clinical examination or medical history (excluding atopic skin signs, symptoms and history)
• 12-lead electrocardiogram with no clinical significant abnormality
• Clinical chemistry hematology and urinalysis results within the laboratory reference ranges or deemed not clinically significant by the Investigator
• A negative screen for drugs of abuse and alcohol
• Body weight between 50-120 kg
• Subjects aged between 18-40 years inclusive must have body mass index (BMI) 18-32 kilogram per square meter (kg/m^2) inclusive. Subjects aged between 41-60 years must have BMI between 18-30 kg/m^2 inclusive.

Exclusion Criteria

• Active concomitant disease, with exception of eczema
• Expected onset of seasonal allergy before the administration of the last dose of study medication
• History of severe exacerbation within 3 years of Day 0
• Recorded use of inhaled short acting beta 2 agonist medication for symptoms within 14 days of Day 0 of: More than 6 doses per day on any 1 day or more than 3 doses per day on 6 or more days
• Any medication other than: inhaled short-acting beta 2 agonist, inhaled corticosteroids, topic eczema treatments (with the exception of fluorinated corticosteroid, dermatological preparations which are not permitted), hormone replacement therapy, vitamin preparation/food supplements, occasional use of proton pump inhibitors, ranitidine, cimetidine, antacids or over-the-counter analgesics
• Treatment within 6 months of Day 0 with any of the following: methylxanthines, inhaled cromones, leukotriene modifiers, anti- immunoglobulin E (IgE), anticholinergics, ketotifen, oral short acting B2 agonists, long-acting B2 agonists, oral or injected corticosteroids
• Treatment of atopic symptoms, other than eczema, within 4 weeks of Day 0
• History of medication that might carry-over effects into the study
• Previously received monoclonal antibody, or a similar related protein, that might sensitize to CAT-354
• Participation in another study within three months of the start of the study or 5 half lives of the previously administered investigational medicinal product (IMP), whichever is longer
• Lower respiratory tract infection within 4 weeks of Day-14
• Any acute illness in the two weeks before Day 0
• Current smokers, those who have smoked in previous year, and those with smoking history of greater than or equal to 10 pack years
• Considered by the investigator to be at risk of transmitting, through blood, the agents responsible for infectious diseases
• Blood donation (550 ml) in the previous 2 months
• Excessive intake of alcohol (more than 21 units a week for females or 28 units a week for males)
• The subject's general practitioner has suggested a reason the subject should not participate in the study
• The Investigator considers the subject should not take part for any reason.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

MedImmune LLC

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

MedImmune LLC

Role: STUDY_DIRECTOR

MedImmune LLC

Locations

Chiltern International Limited

Slough, Berkshire, United Kingdom

Countries

United Kingdom

References

Singh D, Kane B, Molfino NA, Faggioni R, Roskos L, Woodcock A. A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma. BMC Pulm Med. 2010 Jan 8;10:3. doi: 10.1186/1471-2466-10-3.

Reference Type: BACKGROUND

PMID: 20064211 (View on PubMed)

Other Identifiers

2006-003199-36

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

CAT-354-0602

Identifier Type: -

Identifier Source: org_study_id